FDA Approves GE's Vizamyl PET Radiotracer for Dementia

October 25, 2013 -- U.S. physicians looking to detect early signs of Alzheimer's disease now have a second tool in their arsenal with the U.S. Food and Drug Administration's approval of Vizamyl (flutemetamol F-18 injection), a radiopharmaceutical from GE Healthcare for use with PET imaging of the brain in adults being evaluated for Alzheimer's and dementia.

For further information, go to:  http://www.auntminnie.com/index.aspx?sec=log&URL=http%3a%2f%2fwww.auntminnie.com%2findex.aspx%3fsec%3dsup%26sub%3dmol%26pag%3ddis%26itemid%3d105228%26wf%3d5675